On December 18, 2024, MetaVia Inc. (NASDAQ:MTVA) announced positive topline results from the 16-week Phase 2a clinical trial of DA-1241 in patients with presumed metabolic dysfunction-associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback